Nurix Therapeutics is expected to report Q2 2026 revenue of $18.52 million and a loss of $0.73 per share, while the current $28.45 stock price remains significantly below the $35.12 average analyst price target. The primary focus for investors remains the clinical trajectory and upcoming pivotal trial designs for NX-5948, their lead BTK degrader for B-cell malignancies.
Following positive data presentations at major oncology conferences, analysts are looking for further confirmation of the drug's safety profile and duration of response. Additionally, updates on the company's strategic collaborations with Sanofi and Gilead will be critical for assessing the long-term potential of the Degronimid platform.